Published in Br J Cancer on July 15, 2002
Site and timing of first relapse in stage III melanoma patients: implications for follow-up guidelines. J Clin Oncol (2010) 1.15
Serum microRNAs as biomarkers for recurrence in melanoma. J Transl Med (2012) 1.06
A Global Review of Melanoma Follow-up Guidelines. J Clin Aesthet Dermatol (2013) 0.97
Racial differences in survival after surgical treatment for melanoma. Ann Surg Oncol (2011) 0.95
To what extent are current guidelines for cutaneous melanoma follow up based on scientific evidence? Int J Clin Pract (2014) 0.91
Variability in melanoma post-treatment surveillance practices by country and physician specialty: a systematic review. Melanoma Res (2012) 0.84
Targeted melanoma imaging and therapy with radiolabeled alpha-melanocyte stimulating hormone peptide analogues. G Ital Dermatol Venereol (2010) 0.82
Routine Computer Tomography Imaging for the Detection of Recurrences in High-Risk Melanoma Patients. Ann Surg Oncol (2017) 0.79
Detection of melanoma nodal metastases; differences in detection between elderly and younger patients do not affect survival. Ann Surg Oncol (2010) 0.78
Long-term follow-up for melanoma patients: is there any evidence of a benefit? Surg Oncol Clin N Am (2015) 0.78
Utility of 3-year torso computed tomography and head imaging in asymptomatic patients with high-risk melanoma. Melanoma Res (2011) 0.76
Outpatient Follow-up and Secondary Prevention for Melanoma Patients. Cancers (Basel) (2010) 0.75
It is never too late: ultra-late recurrence of melanoma with distant metastases. BMJ Case Rep (2012) 0.75
Cost-Effectiveness of Drug Treatments for Advanced Melanoma: A Systematic Literature Review. Pharmacoeconomics (2017) 0.75
NIH Consensus conference. Diagnosis and treatment of early melanoma. JAMA (1992) 2.12
Use of chest radiography in the initial evaluation of patients with localized melanoma. Arch Dermatol (1998) 2.01
A prospective randomized study of follow-up after radical surgery for colorectal cancer. Br J Surg (1997) 1.87
An estimate of the annual direct cost of treating cutaneous melanoma. J Am Acad Dermatol (1998) 1.76
Factors affecting survival following local, regional, or distant recurrence from localized melanoma. J Surg Oncol (1998) 1.57
A rational approach to melanoma follow-up in patients with primary cutaneous melanoma. Scottish Melanoma Group. Br J Dermatol (1999) 1.57
Follow-up of colorectal cancer: a meta-analysis. Dis Colon Rectum (1998) 1.27
Follow-up recommendations for patients with American Joint Committee on Cancer Stages I-III malignant melanoma. Cancer (1999) 1.22
Utility of follow-up tests for detecting recurrent disease in patients with malignant melanomas. JAMA (1995) 1.15
The multidisciplinary melanoma clinic: a cost outcomes analysis of specialty care. J Am Acad Dermatol (1998) 1.08
Melanoma recurrence surveillance. Patient or physician based? Ann Surg (1995) 1.03
Follow-up in stage I cutaneous malignant melanoma: an audit. Clin Oncol (R Coll Radiol) (1993) 0.94
Cost-effectiveness of surveillance of stage I melanoma. A retrospective appraisal based on a 10-year experience in a dermatology department in France. Dermatology (1995) 0.88
Impact on survival by method of recurrence detection in stage I and II cutaneous melanoma. Ann Surg Oncol (1998) 0.87
Data on first recurrence after treatment for malignant melanoma in a large patient population. Plast Reconstr Surg (1993) 0.85
Evaluation of staging workup in malignant melanoma. Arch Surg (1989) 0.85
Laboratory tests and imaging studies in patients with cutaneous malignant melanomas: a survey of experienced physicians. J Am Acad Dermatol (1997) 0.84
Laboratory tests and imaging studies in patients with cutaneous malignant melanoma. J Am Acad Dermatol (1998) 0.83
Follow-up recommendations for patients with stage I malignant melanoma. J Dermatol Surg Oncol (1994) 0.82
Life-long screening of patients with intermediate-thickness cutaneous melanoma for asymptomatic pulmonary recurrences: a cost-effectiveness analysis. Cancer (1997) 0.81
The value of staging and serial follow-up investigations in patients with completely resected, primary, cutaneous malignant melanoma. Br J Surg (1985) 0.81
Ultrasonographic evaluation of superficial lymph node metastases in melanoma. Eur J Radiol (1997) 0.81
Consensus on the management of melanoma of the skin in The Netherlands. Dutch Melanoma Working Party. Eur J Cancer (1992) 0.80
Metastatic disease in patients with newly diagnosed malignant melanoma. J Surg Oncol (1987) 0.78
Melanoma follow-up: protocols and practice. Br J Dermatol (2000) 0.78
Staging evaluation and surveillance for melanoma patients in a fiscally restrictive medical environment. A commentary. Surg Clin North Am (1996) 0.78
[Malignant melanoma: which examinations are useful in staging and follow-up?]. Dtsch Med Wochenschr (1986) 0.77
Stage I-II melanoma: the value of metastatic work-up. Oncology (1987) 0.77
Which type of follow-up? Hepatogastroenterology (2000) 0.77
Usefulness of paraclinical follow-up in stage I melanoma. Arch Dermatol (1997) 0.77
Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol (2000) 9.70
Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med (1998) 7.48
Human papillomavirus infections in nonmelanoma skin cancers from renal transplant recipients and nonimmunosuppressed patients. J Natl Cancer Inst (1996) 2.28
Lack of clinical efficacy of imatinib in metastatic melanoma. Br J Cancer (2005) 1.66
Differential influence of vemurafenib and dabrafenib on patients' lymphocytes despite similar clinical efficacy in melanoma. Ann Oncol (2014) 1.63
[A simple xenon lamp for the determination of photoallergies]. Strahlentherapie (1967) 1.63
Melanocytes as "sensory" and regulatory cells in the epidermis. J Theor Biol (1993) 1.55
Human mast cells produce IL-8. J Immunol (1993) 1.44
Clinical phase II study of pegylated liposomal doxorubicin as second-line treatment in disseminated melanoma. Onkologie (2004) 1.43
Expression of interleukin-8 detected by in situ hybridization correlates with worse prognosis in primary cutaneous melanoma. J Pathol (1999) 1.40
TERT promoter mutations in ocular melanoma distinguish between conjunctival and uveal tumours. Br J Cancer (2013) 1.38
Increased expression of epidermal fatty acid binding protein, cofilin, and 14-3-3-sigma (stratifin) detected by two-dimensional gel electrophoresis, mass spectrometry and microsequencing of drug-resistant human adenocarcinoma of the pancreas. Electrophoresis (1999) 1.30
Reduced serum 25-hydroxyvitamin D levels in stage IV melanoma patients. Anticancer Res (2009) 1.29
Phase 2 trial of vaccination with tyrosinase peptides and granulocyte-macrophage colony-stimulating factor in patients with metastatic melanoma. J Immunother (2000) 1.27
A ninth complementation group in xeroderma pigmentosum, XP I. Mutat Res (1985) 1.26
Serological detection of cutaneous T-cell lymphoma-associated antigens. Proc Natl Acad Sci U S A (2001) 1.24
The chemokine RANTES is secreted by human melanoma cells and is associated with enhanced tumour formation in nude mice. Br J Cancer (1999) 1.22
Interferon alfa-2a and interleukin-2 with or without cisplatin in metastatic melanoma: a randomized trial of the European Organization for Research and Treatment of Cancer Melanoma Cooperative Group. J Clin Oncol (1997) 1.20
Prognostic value of ERBB-1, VEGF, cyclin A, FOS, JUN and MYC in patients with squamous cell lung carcinomas. Br J Cancer (1998) 1.19
In vitro evaluation of bendamustine induced apoptosis in B-chronic lymphocytic leukemia. Leukemia (2002) 1.19
Deficient IL-12p70 secretion by dendritic cells based on IL12B promoter genotype. Genes Immun (2004) 1.18
Biomarkers in melanoma. Ann Oncol (2009) 1.17
Drug-resistance in human melanoma. Int J Cancer (2001) 1.15
[Xeroderma pigmentosum and pigmented xerodermoid. Clinical and molecular biological studies]. Schweiz Med Wochenschr (1970) 1.15
[Investigations on the dark repair mechanism of the human epidermis]. Arch Klin Exp Dermatol (1969) 1.14
Identification of novel proteins associated with the development of chemoresistance in malignant melanoma using two-dimensional electrophoresis. Electrophoresis (2000) 1.14
[Effects of UV-C and of 8-MOP + UV-A on the T- and B-population of human lymphocytes in vitro (author's transl)]. Arch Dermatol Res (1977) 1.12
Rapid screening assay for mutagen sensitivity and DNA repair capacity in human peripheral blood lymphocytes. Mutagenesis (2001) 1.12
Malignant proliferating trichilemmal cyst. J Am Acad Dermatol (1995) 1.11
Xeroderma pigmentosum. Int J Dermatol (1986) 1.11
A randomised, phase II study of intetumumab, an anti-αv-integrin mAb, alone and with dacarbazine in stage IV melanoma. Br J Cancer (2011) 1.10
Small molecules and targeted therapies in distant metastatic disease. Ann Oncol (2009) 1.08
New form of molecular defect in xeroderma pigmentosum. Nature (1970) 1.07
Arsenic as an inhibitor of the enzymes concerned in cellular recovery (dark repair). Ger Med Mon (1969) 1.06
Acquired resistance of melanoma cells to the antineoplastic agent fotemustine is caused by reactivation of the DNA repair gene MGMT. Int J Cancer (2001) 1.05
Effects of 8-methoxypsoralen (8-MOP) and UVA on human lymphocytes. Arch Dermatol Res (1977) 1.04
Human dendritic cells infected by Listeria monocytogenes: induction of maturation, requirements for phagolysosomal escape and antigen presentation capacity. Eur J Immunol (2000) 1.04
Treatment of disseminated ocular melanoma with sequential fotemustine, interferon alpha, and interleukin 2. Br J Cancer (2002) 1.03
DFNA5 (ICERE-1) contributes to acquired etoposide resistance in melanoma cells. FEBS Lett (2001) 1.03
Dose-dependent severe cutaneous reactions to imatinib. Br J Cancer (2003) 1.03
[Molecular biology of arsenic carcinogenesis]. Arch Klin Exp Dermatol (1970) 1.01
Altered DNA repair capacity and bleomycin sensitivity as risk markers for non-small cell lung cancer. Int J Cancer (2001) 0.99
Cutaneous large B-cell lymphoma of the leg masquerading as a chronic venous ulcer. Br J Dermatol (2002) 0.97
Xeroderma pigmentosum complementation group XP-I withdrawn. Mutat Res (1989) 0.97
Clinical symptoms and DNA repair characteristics of xeroderma pigmentosum patients from Germany. Cancer Res (1991) 0.97
Corticosteroid-induced chemotherapy resistance in urological cancers. Cancer Biol Ther (2006) 0.97
Identification of differentially expressed genes in human melanoma cells with acquired resistance to various antineoplastic drugs. Int J Cancer (2000) 0.96
Substance use and sexual risk behaviour among HIV-positive men who have sex with men in specialized out-patient clinics. HIV Med (2012) 0.96
The polymerase chain reaction. Method and applications in dermatopathology. Am J Dermatopathol (1993) 0.96
Expression and functional activity of the IL-8 receptor type CXCR1 and CXCR2 on human mast cells. J Immunol (1998) 0.96
MGMT gene promoter methylation correlates with tolerance of temozolomide treatment in melanoma but not with clinical outcome. Br J Cancer (2010) 0.96
Expression of cyclins and cyclin dependent kinases in human benign and malignant melanocytic lesions. J Clin Pathol (2001) 0.96
Vaccination with IL-12 gene-modified autologous melanoma cells: preclinical results and a first clinical phase I study. Gene Ther (1998) 0.95
Light-induced skin cancer and prolonged uv-erythema. Arch Dermatol Res (1980) 0.95
Xeroderma pigmentosum patients from Germany: clinical symptoms and DNA repair characteristics. Arch Dermatol Res (1982) 0.94
Risk factors of the cutaneous melanoma phenotype. Arch Dermatol Res (1981) 0.94
[Experimental herpes simplex virus infection of the skin of hairless mice]. Arch Klin Exp Dermatol (1970) 0.93
Identification of a new HLA-A(*)0201-restricted T-cell epitope from the tyrosinase-related protein 2 (TRP2) melanoma antigen. Int J Cancer (2000) 0.93
Polidocanol foam sclerotherapy is a new and effective treatment for post-operative lymphorrhea and lymphocele. J Eur Acad Dermatol Venereol (2010) 0.92
Sister chromatid exchange (SCE) in human lymphocytes. Effect of UV C irradiation and age. Arch Dermatol Res (1979) 0.92
Heterogeneity of xeroderma pigmentosum (XP); variability and stability within and between the complementation groups C, D, E, I and variants. Photodermatol (1986) 0.92
[Pigmented xerodermoid. A defect of recombinational recovery following UV-injuries]. Arch Dermatol Forsch (1971) 0.91
Dysplastic nevus syndrome: ultraviolet hypermutability confirmed in vitro by elevated sister chromatid exchanges. Dermatologica (1986) 0.91
[Excision repair in lymphocytes of psoriasis (author's transl)]. Arch Dermatol Forsch (1975) 0.91
Modulation of DNA topoisomerase II activity and expression in melanoma cells with acquired drug resistance. Br J Cancer (2000) 0.91
Photoallergy to "jadit" with photo cross-reactions to derivative of sulfanilamide. Int Arch Allergy Appl Immunol (1965) 0.91
Expression of heat shock protein 27 in chromomycosis. Mycoses (1998) 0.91
Temozolomide plus pegylated interferon alfa-2b as first-line treatment for stage IV melanoma: a multicenter phase II trial of the Dermatologic Cooperative Oncology Group (DeCOG). Ann Oncol (2008) 0.91
SEREX identification of new tumour-associated antigens in cutaneous T-cell lymphoma. Br J Dermatol (2004) 0.91
Pigmented Xerodermoid: first report of a family. Bull Cancer (1978) 0.90
Functional HLA-DM on the surface of B cells and immature dendritic cells. EMBO J (2000) 0.90
Vaccination with IL-7 gene-modified autologous melanoma cells can enhance the anti-melanoma lytic activity in peripheral blood of patients with a good clinical performance status: a clinical phase I study. Br J Cancer (1998) 0.90
Characterization of sunburn cells after exposure to ultraviolet light. Photodermatol Photoimmunol Photomed (1995) 0.90
Dexamethasone desensitizes hepatocellular and colorectal tumours toward cytotoxic therapy. Cancer Lett (2005) 0.90
Cellular predictive factors for the drug response of lung cancer. Anticancer Res (2000) 0.90
Acrokeratoelastoidosis. Humangenetik (1973) 0.90
Expression of p53 protein in malignant melanoma: clinicopathological and prognostic implications. Br J Dermatol (1995) 0.90
Malignant melanoma in southern Germany: different predictive value of risk factors for melanoma subtypes. Dermatologica (1991) 0.89
[On the histology of photoallergic test reactions]. Dermatologica (1967) 0.89
Patterns of constitutive and IFN-gamma inducible expression of HLA class II molecules in human melanoma cell lines. Immunogenetics (2006) 0.88
[Photoallergy caused by 4-chloro-2-hydroxybonzoic acid-n-bytlamide. I. Light biological studies on antigen formation]. Arch Klin Exp Dermatol (1968) 0.88
Treatment of severe psoriasis with etanercept in a pancreas-kidney transplant recipient. Transplant Proc (2012) 0.88
Characterization of gene regulatory elements for selective gene expression in human melanoma cells. Biochem Biophys Res Commun (1995) 0.88
Hepatic intra-arterial versus intravenous fotemustine in patients with liver metastases from uveal melanoma (EORTC 18021): a multicentric randomized trial. Ann Oncol (2014) 0.88
The German melanoma registry and environmental risk factors implied. Recent Results Cancer Res (1993) 0.88
β-Blocker use and all-cause mortality of melanoma patients: results from a population-based Dutch cohort study. Eur J Cancer (2013) 0.87
[X-ray therapy of hemangiomatas (author's transl)]. Dermatologica (1976) 0.87
Expression of DNA repair proteins hMSH2, hMSH6, hMLH1, O6-methylguanine-DNA methyltransferase and N-methylpurine-DNA glycosylase in melanoma cells with acquired drug resistance. Int J Cancer (1999) 0.86
Enhanced expression of human ABC-transporter tap is associated with cellular resistance to mitoxantrone. FEBS Lett (2001) 0.86
Prognostic implications of cyclins (D1, E, A), cyclin-dependent kinases (CDK2, CDK4) and tumor-suppressor genes (pRB, p16INK4A) in childhood acute lymphoblastic leukemia. Int J Cancer (1997) 0.86
Xeroderma pigmentosum: heterogeneous syndrome and model for UV carcinogenesis. Bull Cancer (1978) 0.86
Alterations of DNA repair in melanoma cell lines resistant to cisplatin, fotemustine, or etoposide. J Invest Dermatol (2000) 0.86
Interleukin-6 expression in the skin of patients with lupus erythematosus. Exp Dermatol (1995) 0.86
Clinical implications of cyclins, cyclin-dependent kinases, RB and E2F1 in squamous-cell lung carcinoma. Int J Cancer (1998) 0.86
Sun and skin. Dermatologica (1975) 0.85
Complete remission of multiple satellite and in-transit melanoma metastases after sequential treatment with isolated limb perfusion and topical imiquimod. Br J Dermatol (2006) 0.85